BUSINESS MODEL DEVELOPMENT FOR ORPHAN DRUG BUSINESS IN INDONESIA (CASE STUDY: IDIOPATHIC PULMONARY FIBROSIS DRUG)
Over past 25 years, drug research and development was focus to discover treatment for debilitating diseases with high prevalence. Nowadays, many innovative global pharmaceutical companies interest and start to invest their budget and resources to discover new drugs taking a targeted approach to atta...
Saved in:
| Main Author: | |
|---|---|
| Format: | Theses |
| Language: | Indonesia |
| Online Access: | https://digilib.itb.ac.id/gdl/view/35809 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Institut Teknologi Bandung |
| Language: | Indonesia |
| Summary: | Over past 25 years, drug research and development was focus to discover treatment for debilitating diseases with high prevalence. Nowadays, many innovative global pharmaceutical companies interest and start to invest their budget and resources to discover new drugs taking a targeted approach to attack the underlying causes of rare diseases, which is called orphan drug. To run an orphan drug business in current Indonesian healthcare landscape, there are some key internal and external factors influencing the business, but mainly driven by universal healthcare insurance or Jaminan Kesehatan Nasional program, treatment cost and lack of physicians’ awareness.
The objective of this study is to propose a new business model canvas for an orphan drug business in Indonesia, by using Idiopathic Pulmonary Fibrosis drug, Pirfenidone, as case study. The analysis of external factors will be done through PEST (Political, Economic, Social, Technological), Porter's 5 Forces and competitive analysis. The internal analysis will be based on VRIO and value chain analysis. The results will be used to identify SWOT of Pirfenidone and its company, to develop TOWS matrix. Porter Generic Strategy and Diamond Strategy model to obtain new ideas and strategies for the company, then to propose a new business model canvas to the company. The research method is qualitative by collecting data through interview and data observation.
The analysis showed that the company has not optimally used their internal resources to create innovative and effective strategies to utilize opportunities and cope challenges. It is recommended for management to reorganize internal team, equip them with advanced knowledge on developing orphan drug business and optimally utilize global resources on orphan drug and digital platform development. The brand team should also initiate innovative and unique partnership with several stakeholders, such as government and patient organization, and not only focus but without eliminating engagement with clinicians and medical association. |
|---|